Click Therapeutics

News

Boehringer, Click DTx for schizophrenia clears pivotal trial

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Click, Boehringer DTx for schizophrenia passes phase 3 test

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.

News

App to support people with depression launches in GB

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.

News

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

News

Trial of Click's DTx for migraine sets up FDA filing

Click Therapeutics' digital therapeutic (DTx) for migraine has hit the mark in a late-stage study using an endpoint commonly used to test drug therapies, which it claims is a first for the

News

prescription digital therapeutic on a smartphone

Otsuka, Click's depression DTx launches in the US

An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.

Boehringer, Click DTx for schizophrenia clears pivotal trial

Click, Boehringer DTx for schizophrenia passes phase 3 test

App to support people with depression launches in GB

FDA clears first migraine DTx from Click Therapeutics

Trial of Click's DTx for migraine sets up FDA filing

Otsuka, Click's depression DTx launches in the US

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Click Therapeutics

Editor's Picks